These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22904612)

  • 21. Adalimumab in psoriatic arthritis.
    Salvarani C; Pipitone N; Catanoso M; Chiarolanza I; Boiardi L; Caruso A; Pazzola G; Macchioni P; Di Lernia V; Albertini G
    J Rheumatol Suppl; 2012 Jul; 89():77-81. PubMed ID: 22751600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.
    Mease PJ; Genovese MC; Weinblatt ME; Peloso PM; Chen K; Othman AA; Li Y; Mansikka HT; Khatri A; Wishart N; Liu J
    Arthritis Rheumatol; 2018 Nov; 70(11):1778-1789. PubMed ID: 29855175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
    Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
    Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.
    Behrens F; Koehm M; Arndt U; Wittig BM; Greger G; Thaçi D; Scharbatke E; Tony HP; Burkhardt H
    J Rheumatol; 2016 Mar; 43(3):632-9. PubMed ID: 26669916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
    J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
    Yamaguchi A; Hirata S; Kubo S; Fukuyo S; Hanami K; Nakano K; Nakayamada S; Saito K; Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):799-806. PubMed ID: 31814496
    [No Abstract]   [Full Text] [Related]  

  • 30. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
    Nakagawa H; Tanaka Y; Sano S; Kameda H; Taniguchi A; Kashiwagi T; Kawaberi T; Kimura J; Morita A
    Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
    Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
    J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
    Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G
    Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
    Smolen JS; Sebba A; Ruderman EM; Schulze-Koops H; Sapin C; Gellett AM; Sprabery AT; Li L; de la Torre I; Gallo G; Liu-Leage S; Pillai S; Reis P; Nash P
    Rheumatol Ther; 2020 Dec; 7(4):1021-1035. PubMed ID: 33200394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
    Mease P; Kavanaugh A; Gladman D; FitzGerald O; Soriano ER; Nash P; Feng D; Lertratanakul A; Douglas K; Lippe R; Gossec L
    Rheumatol Ther; 2022 Aug; 9(4):1181-1191. PubMed ID: 35606663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
    Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
    Tanaka Y; Yamanaka H; Ishiguro N; Miyasaka N; Kawana K; Kimura J; Agata N; Takeuchi T
    Arthritis Res Ther; 2017 Mar; 19(1):56. PubMed ID: 28288682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study.
    Perrotta FM; Lubrano E
    Postgrad Med; 2016 Sep; 128(7):693-6. PubMed ID: 27494077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.